Basic Stats
| CIK | 1323885 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AtriCure, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| July 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| July 30, 2025 |
As filed with the Securities and Exchange Commission on July 30, 2025 S-8 As filed with the Securities and Exchange Commission on July 30, 2025 Registration No. |
|
| July 30, 2025 |
Calculation of Filing Fee Tables S-8 AtriCure, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 1,700,000 $ 30.60 $ 52,020,000.00 0.0001531 $ 7,965.00 Total Offering A |
|
| July 29, 2025 |
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 Exhibit 99.1 For immediate release July 29, 2025 AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 •Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) •Net loss of $6.2 million – an improvement of $1.8 million year over year •Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year •Genera |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2025 AtriCure, Inc. |
|
| May 29, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 This report for the year ended December 31, 2024 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. |
|
| May 20, 2025 |
Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 19, 2025) 1. Purpose. The purpose of the AtriCure, Inc. Amended and Restated 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective di |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 AtriCure, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| April 30, 2025 |
Form of Performance Share Award Agreement for Awards Granted in 2025. Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2023 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”), |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 AtriCure, Inc. |
|
| April 29, 2025 |
AtriCure Reports First Quarter 2025 Financial Results Exhibit 99.1 For immediate release April 29, 2025 AtriCure Reports First Quarter 2025 Financial Results •Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) •Net loss of $6.7 million – an improvement of $6.5 million year over year •Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio, April 29, 2025 – AtriCure, Inc |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 26, 2025 |
Analyst and Investor Day Michael Carrel, CEO © 2025 AtriCure, Inc. All rights reserved. March 2025 Exhibit 99.1 © 2025 AtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature |
|
| March 26, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2025 AtriCure, Inc. |
|
| February 14, 2025 |
EX-4.6 Exhibit 4.6 ATRICURE, INC. INDENTURE Dated as of [ ] U.S. Bank Trust Company, National Association, Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article 2 THE NOTES 6 Section 2.1 Issuable in |
|
| February 14, 2025 |
EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 14, 2025 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| February 14, 2025 |
Form of Indemnity Agreement with Directors and Executive Officers. Exhibit 10.18 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “AGREEMENT”) is made and effective as of this day of , 20 by and between ATRICURE, INC., a Delaware corporation (the “COMPANY”), and (“INDIVIDUAL”). RECITALS WHEREAS, Individual performs a valuable service to the Company in Individual’s capacity as a member of the Board of Directors of the Company; WHEREAS, the stockholders of the Co |
|
| February 14, 2025 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Canada, Inc., incorporated in Canada Atri |
|
| February 12, 2025 |
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results Exhibit 99.1 For immediate release February 12, 2025 AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results •Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year •Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year •Launched cryoSPHERE®+, cryoSPHERE MAX™ and AtriClip® FLEX-Mini™ devices in the United S |
|
| February 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 AtriCure, Inc. |
|
| January 13, 2025 |
Exhibit 99.1 For immediate release January 13, 2025 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day MASON, Ohio, January 13, 2025 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) managemen |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 AtriCure, Inc. |
|
| January 13, 2025 |
Creating a World Class Platform January 2025 © 2025 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that |
|
| November 14, 2024 |
ATRC / AtriCure, Inc. / Hood River Capital Management LLC Passive Investment SC 13G 1 o102246sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| October 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| October 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 AtriCure, Inc. |
|
| October 29, 2024 |
AtriCure Reports Third Quarter 2024 Financial Results Exhibit 99.1 For immediate release October 29, 2024 AtriCure Reports Third Quarter 2024 Financial Results •Worldwide revenue of $115.9 million – an increase of 17.9% year over year •U.S. revenue of $95.5 million – an increase of 16.8% year over year •Achieved 20% growth on revenues from open appendage management devices in the U.S. •International revenue of $20.5 million – an increase of 23.3% yea |
|
| July 31, 2024 |
Amended and Restated Bylaws (marked to show changes). comparisonresultjuly2024 Exhibit 3.3 FOURTH AMENDED AND RESTATED BYLAWS OF ATRICURE, INC. (a Delaware corporation) i TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ......................................................................................... 1 1.1 REGISTERED OFFICE. ........................................................................................ 1 1.2 OTHER OFFICES. ..... |
|
| July 31, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 31, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees t |
|
| July 31, 2024 |
july2024atricureamendeda Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ATRICURE, INC. (a Delaware corporation) i TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ......................................................................................... 1 1.1 REGISTERED OFFICE. ........................................................................................ 1 1.2 OTHER OFFICES. ............ |
|
| July 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 AtriCure, Inc. |
|
| July 30, 2024 |
AtriCure Reports Second Quarter 2024 Financial Results Exhibit 99.1 For immediate release July 30, 2024 AtriCure Reports Second Quarter 2024 Financial Results •Worldwide revenue of $116.3 million – an increase of 15.2% year over year •Positive cash flow generation of $8.1 million in second quarter 2024 MASON, Ohio, July 30, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), le |
|
| May 31, 2024 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 This report for the year ended December 31, 2023 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. |
|
| May 14, 2024 |
AtriCure, Inc. 2023 Stock Incentive Plan (Amended and Restated as of May 13, 2024). Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 13, 2024) 1. Purpose. The purpose of the AtriCure, Inc. Amended and Restated 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective di |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 AtriCure, Inc. |
|
| May 14, 2024 |
Restated Certificate of Incorporation. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ATRICURE, INC. (Originally incorporated on October 31, 2000) ARTICLE I The name of the corporation is AtriCure, Inc. (the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, County of New Castle, City of Wilmington, DE 19801. The registered agent at this address is Nationa |
|
| May 2, 2024 |
Form of Performance Stock Unit Award Agreement for Employees. Exhibit 10.2 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as it may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on March 1, 2024 (the “Grant Date”) a forfeitable Performance Stock Unit Award (the “Performance Unit Award”) repr |
|
| May 2, 2024 |
Form of Performance Share Award Agreement for Awards Granted in 2024. Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE STOCK AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on, 2024 (the “Grant Date”) a Performance Stock Award (the “Performance Stock Award”) of forfeitable shares of the Company |
|
| May 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| May 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 AtriCure, Inc. |
|
| May 1, 2024 |
AtriCure Reports First Quarter 2024 Financial Results Exhibit 99.1 For immediate release May 1, 2024 AtriCure Reports First Quarter 2024 Financial Results •Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio, May 1, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, to |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. |
|
| February 16, 2024 |
Exhibit 10.24 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as it may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on , 2023 (the “Grant Date”) a forfeitable Restricted Stock Unit Award (the “Restricted Unit Award”) representing |
|
| February 16, 2024 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Canada, Inc., incorporated in Canada Atri |
|
| February 16, 2024 |
Form of Performance Share Award Agreement for Awards Granted in 2023. Exhibit 10.22 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”) |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi |
|
| February 16, 2024 |
Exhibit 19 ATRICURE, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities Amended and restated effective as of March 1, 2023 Executive Summary Insider Trading – (a)It is a violation of US law for directors, officers, employees, and other individuals who possess material nonpublic information regarding the Company to execute transactions in Company Securitie |
|
| February 16, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97 Incentive Compensation Recoupment Policy (the “Policy”) 1.Recoupment. If AtriCure, Inc. (the “Company”) is required to prepare a Restatement, the Company’s board of directors (the “Board”) shall, unless the Board’s Compensation Committee determines it to be Impracticable, take reasonably prompt action to recoup all Recoverable Compensation from any Covered Person. Subject to applicable |
|
| February 16, 2024 |
Exhibit 10.23 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on , 2023 (the “Grant Date”) a Restricted Stock Award (the “Restricted Stock Award”) of forfeitable shares of the Company’ |
|
| February 15, 2024 |
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results Exhibit 99.1 For immediate release February 15, 2024 AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results •Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year •Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year •Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year •Fu |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 AtriCure, Inc. |
|
| February 14, 2024 |
ATRC / AtriCure, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 13, 2024 |
ATRC / AtriCure, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0363-atricureinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: AtriCure Inc Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p |
|
| February 1, 2024 |
ATRC / AtriCure, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 8, 2024 |
EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of January 5, 2024 among ATRICURE, INC. and ATRICURE, LLC, as Borrowers, The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A. and SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY as Joint Lead Arrangers and Joint Bookrunners ASSET BASED LENDING TABLE OF CONTEN |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 For immediate release January 8, 2024 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024 MASON, Ohio, January 8, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, ann |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 AtriCure, Inc. |
|
| January 4, 2024 |
AtriCure Appoints Shlomi Nachman to the Board of Directors Exhibit 99.1 For immediate release January 4, 2024 AtriCure Appoints Shlomi Nachman to the Board of Directors MASON, Ohio, January 4, 2024—AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Direct |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 AtriCure, Inc. |
|
| December 8, 2023 |
ATRC / Atricure Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0015-atricureinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: AtriCure Inc Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: November 30, 2023 Check the appropriate box to designate the rule p |
|
| November 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| November 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 AtriCure, Inc. |
|
| November 1, 2023 |
AtriCure Reports Third Quarter 2023 Financial Results Exhibit 99.1 For immediate release November 1, 2023 AtriCure Reports Third Quarter 2023 Financial Results •Worldwide revenue of $98.3 million – an increase of 18.1% year over year •U.S. revenue of $81.7 million – an increase of 17.1% year over year •International revenue of $16.6 million – an increase of 23.2% year over year •Net loss of $9.1 million – an improvement of $3.2 million year over year |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No. |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023 S-8 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No. |
|
| July 26, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee |
|
| July 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| July 26, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee |
|
| July 25, 2023 |
AtriCure Reports Second Quarter 2023 Financial Results Exhibit 99.1 For immediate release July 25, 2023 AtriCure Reports Second Quarter 2023 Financial Results •Worldwide revenue of $100.9 million – an increase of 19.4% year over year •U.S. revenue of $84.9 million – an increase of 19.1% year over year •International revenue of $16.0 million – an increase of 20.7% year over year •Net loss of $5.1 million – an improvement of $9.7 million year over year |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2023 AtriCure, Inc. |
|
| May 26, 2023 |
Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN 1. Purpose. The purpose of the AtriCure, Inc. 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective directors, officers, employees, consultants and advisors) of the |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2023 AtriCure, Inc. |
|
| May 26, 2023 |
Exhibit 10.2 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN (AMENDED AND RESTATED EFFECTIVE MAY 25, 2023) 1. Purpose. The purposes of the Plan are as follows: a.To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an “employee stock purchase plan” within |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. |
|
| May 24, 2023 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD EX-1.01 2 formsd-exhibit101.htm EX-1.01 Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 This report for the year ended December 31, 2022 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosur |
|
| May 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 AtriCure, Inc. |
|
| May 2, 2023 |
AtriCure Reports First Quarter 2023 Financial Results Exhibit 99.1 For immediate release May 2, 2023 AtriCure Reports First Quarter 2023 Financial Results •Worldwide revenue of $93.5 million – an increase of 25.4% year over year •U.S. revenue of $78.2 million – an increase of 25.6% year over year •International revenue of $15.3 million – an increase of 24.4% year over year •Net loss of $6.5 million – an improvement of $8.7 million year over year •Pos |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 22, 2023 |
Exhibit 10.19 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”) |
|
| February 22, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specified i |
|
| February 22, 2023 |
atricurecodexofxconduct Code of Conduct Exhibit 14 From Our Chief Executive Officer and Chief Compliance Officer We are part of a truly remarkable organization. |
|
| February 22, 2023 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Hong Kong Limited, incorporated in Hong K |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 AtriCure, Inc. |
|
| February 21, 2023 |
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results Exhibit 99.1 For immediate release February 21, 2023 AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results •2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year •2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year •2022 International revenue of $53.2 million – an increase of 17.7% in 2022 MASON, Ohio, February 21, 2023 – AtriCure, |
|
| February 14, 2023 |
ATRC / AtriCure Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2023 |
ATRC / AtriCure Inc. / ALGER ASSOCIATES INC - ATRICURE, INC. Passive Investment SC 13G/A 1 d62536dsc13ga.htm ATRICURE, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 9, 2023 |
ATRC / AtriCure Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 3, 2023 |
ATRC / AtriCure Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 9, 2023 |
EX-99.1 2 atrc-20230109xexx991.htm EX-99.1 Exhibit 99.1 For immediate release January 9, 2023 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023 MASON, Ohio, January 9, 2023 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 AtriCure, Inc. |
|
| January 9, 2023 |
Creating a World Class Platform JANUARY 2023 © 2023 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking s |
|
| November 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| November 1, 2022 |
AtriCure Reports Third Quarter 2022 Financial Results Exhibit 99.1 For immediate release November 1, 2022 AtriCure Reports Third Quarter 2022 Financial Results MASON, Ohio, November 1, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. ?We are proud |
|
| November 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 AtriCure, Inc. |
|
| August 3, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid |
|
| August 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 2, 2022 |
Creating a World Class Afib Platform AUGUST 2022 © 2022 AtriCure, Inc. All rights reserved. INVESTOR PRESENTATION Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statement |
|
| August 2, 2022 |
AtriCure Reports Second Quarter 2022 Financial Results Exhibit 99.1 For immediate release August 2, 2022 AtriCure Reports Second Quarter 2022 Financial Results MASON, Ohio, August 2, 2022 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 AtriCure, Inc. |
|
| May 31, 2022 |
SD 1 atrc-formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 34-1940305 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7555 Innovation Way Mason, OH 45040 (Address of principal executiv |
|
| May 31, 2022 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 This report for the year ended December 31, 2021 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2022 AtriCure, Inc. |
|
| May 27, 2022 |
Exhibit 10.1 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 25, 2022) TABLE OF CONTENTS 1 Purposes 1 2 Definitions 1 3 Administration of the Plan 3 (a) Authority of Committee 3 (b) Binding Authority 4 (c) Delegation of Authority 4 4 Eligibility 4 5 Common Shares Subject to the Plan 4 (a) Authorized Number of Common Shares 4 (b) Share Counting 4 (c) Award Limitations. 5 (d |
|
| May 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 AtriCure, Inc. |
|
| May 3, 2022 |
AtriCure Reports First Quarter 2022 Financial Results Exhibit 99.1 For immediate release May 3, 2022 AtriCure Reports First Quarter 2022 Financial Results MASON, Ohio, May 3, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. ?Our team delivered exc |
|
| May 3, 2022 |
? 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform Exhibit 99.2 This presentation and oral statements made in connection with this presentation contain ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, |
|
| April 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2022 AtriCure, Inc. |
|
| April 13, 2022 |
Exhibit 99.1 For immediate release April 12, 2022 AtriCure Launches EnCompass? Clamp, a part of Isolator Synergy? Ablation System New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio ? (BUSINESS WIRE) ? April 12, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage |
|
| April 11, 2022 |
DEF 14A 1 atrc-def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| April 11, 2022 |
DEFA14A 1 atrc-defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specified i |
|
| February 17, 2022 |
Exhibit 10.21 ATRICURE, INC. EXECUTIVE LEADERSHIP SEVERANCE POLICY 1. Purpose The purpose of the AtriCure, Inc. Executive Leadership Severance Policy (the ?Policy?) is to provide payments to eligible executive officers of AtriCure, Inc. (the ?Company?), other than the Chief Executive Officer, whose employment is involuntarily terminated in certain circumstances not involving a change in control of |
|
| February 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| February 17, 2022 |
EX-25.1 5 d281828dex251.htm EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified i |
|
| February 17, 2022 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company Endoscopic Technologies, LLC, a Delaware limited liability company nContact Surgical LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, inc |
|
| February 17, 2022 |
Exhibit 4.6 ATRICURE, INC. INDENTURE Dated as of [ ] U.S. Bank National Association, Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article 2 THE NOTES 6 Section 2.1 Issuable in Series 6 Section 2.2 Esta |
|
| February 17, 2022 |
Code of Conduct Introduction from Our Chief Executive Officer and Chief Compliance Officer Team AtriCure, We are a part of a truly remarkable organization, and now we must fulfill the legacy started by those who came before us. |
|
| February 17, 2022 |
As filed with the Securities and Exchange Commission on February 17, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2022 AtriCure, Inc. |
|
| February 15, 2022 |
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results Exhibit 99.1 For immediate release February 15, 2022 AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results MASON, Ohio, February 15, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full |
|
| February 14, 2022 |
ATRC / AtriCure Inc. / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2022 |
ATRC / AtriCure Inc. / ALGER ASSOCIATES INC - ATRICURE, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2022 |
ATRC / AtriCure Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 9, 2022 |
ATRC / AtriCure Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
? 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform This presentation and oral statements made in connection with this presentation contain ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure?s e |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 AtriCure, Inc. |
|
| January 10, 2022 |
Exhibit 99.1 For immediate release January 10, 2022 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022 MASON, Ohio, January 10, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announce |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| November 4, 2021 |
Exhibit 10.2 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 1st day of November, 2021, among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as Administrative Agent (?Agent?), (b) SVB, and each other lender and other financial institutions party to the Loan Agreement (as defined b |
|
| November 4, 2021 |
Exhibit 10.1 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2022 1.Purpose. The purposes of the Plan are as follows: (a)To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an ?employee stock purchase plan? withi |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 AtriCure, Inc. |
|
| November 3, 2021 |
AtriCure Reports Third Quarter 2021 Financial Results Exhibit 99.1 For immediate release November 3, 2021 AtriCure Reports Third Quarter 2021 Financial Results MASON, Ohio, November 3, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. ?Our results were driven by strong growth across key product lines, |
|
| August 5, 2021 |
hibi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2021 AtriCure, Inc. |
|
| August 4, 2021 |
Exhibit 99.2 ? AtriCure Investor Presentation Creating a World Class Afib Platform ? 2021 AtriCure, Inc. All rights reserved. AtriCure 1 ? Forward Looking Statements This presentation contains ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results |
|
| August 4, 2021 |
AtriCure Reports Second Quarter 2021 Financial Results Exhibit 99.1 For immediate release August 4, 2021 ? AtriCure Reports Second Quarter 2021 Financial Results MASON, Ohio, August 4, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. ? ?Our second quarter results were driven by outperformance across o |
|
| June 15, 2021 |
AtriCure Names Two New Members to the Board of Directors Exhibit 99.1 For immediate release June 15, 2021 ? ? AtriCure Names Two New Members to the Board of Directors ? MASON, Ohio ? (BUSINESS WIRE) ? June 15, 2021? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. ? |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 AtriCure, Inc. |
|
| May 28, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ? ATRICURE, INC. |
|
| May 28, 2021 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 ? AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 ? This report for the year ended December 31, 2020 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict m |
|
| May 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2021 AtriCure, Inc. |
|
| April 29, 2021 |
Exhibit 99.1 For immediate release April 29, 2021 ? AtriCure?s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients ? FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure?s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% diff |
|
| April 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2021 AtriCure, Inc. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| April 27, 2021 |
AtriCure Reports First Quarter 2021 Financial Results Exhibit 99.1 For immediate release April 27, 2021 ? AtriCure Reports First Quarter 2021 Financial Results MASON, Ohio, April 27, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. ? ?Our growth in the first quarter is a testament of our team?s strong |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2021 AtriCure, Inc. |
|
| April 8, 2021 |
AtriCure Names B. Kristine Johnson Board Chair Exhibit 99.1 For immediate release April 8, 2021 AtriCure Names B. Kristine Johnson Board Chair MASON, Ohio – (BUSINESS WIRE) – April 8, 2021– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2021 AtriCure, Inc. |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 26, 2021 |
Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED [***] ? FIFTH AMENDMENT to Loan and security agreement ? This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 8th day of February, 2021, among (a) SILICON VALLEY BANK, a Cal |
|
| February 26, 2021 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company Endoscopic Technologies, LLC, a Delaware limited liability company nContact Surgical LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, inc |
|
| February 26, 2021 |
Form of First Amendment to Performance Share Award Agreement for Awards Granted in 2019 and 2020. EX-10.19 3 atrc-20201231xex1019.htm EX-10.19 Exhibit 10.19 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN FIRST AMENDMENT TO PERFORMANCE SHARE AWARD AGREEMENT This First Amendment to Performance Share Award Agreement (the "Amendment") is effective as of February 25, 2021 and is entered into by and between AtriCure, Inc., a Delaware corporation (the "Company") and [] (the "Grantee"). WHEREAS, the C |
|
| February 26, 2021 |
EX-10.20 4 atrc-20201231xex1020.htm EX-10.20 Exhibit 10.20 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this |
|
| February 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 AtriCure, Inc. |
|
| February 23, 2021 |
AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results Exhibit 99.1 For immediate release February 23, 2021 ? AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio, February 23, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. ? ?Despite challenges po |
|
| February 16, 2021 |
AtriCure, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 16, 2021 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 11, 2021 |
EX-99.2 3 atrc-20210111xex992.htm EX-99.2 Exhibit 99.2 AtriCure Investor Presentation Creating a World Class Afib Platform January 2021 © 2021 AtriCure, Inc. All rights reserved. AtriCure 1 Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking |
|
| January 11, 2021 |
Exhibit 99.1 For immediate release January 11, 2021 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) MASON, Ohio, January 11, 2021 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) ma |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2021 ATRICURE, INC. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 AtriCure, Inc. |
|
| November 5, 2020 |
EX-99.2 AtriCure Investor Presentation Creating a World Class Afib Platform November 2020 © 2020 AtriCure, Inc. All rights reserved. Exhibit 99.2 This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ material |
|
| November 5, 2020 |
AtriCure Reports Third Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 For immediate release November 5, 2020 AtriCure Reports Third Quarter 2020 Financial Results • Worldwide revenue of $54.8 million – a decrease of 3.3% year over year • U.S. revenue of $44.7 million – a decrease of 3.1% year over year • International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio, November 5, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a lea |
|
| August 10, 2020 |
ATRC / AtriCure, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| August 6, 2020 |
AtriCure Announces Angie Wirick as Chief Financial Officer EX-99.1 3 d941955dex991.htm EX-99.1 Exhibit 99.1 For immediate release August 6, 2020 AtriCure Announces Angie Wirick as Chief Financial Officer MASON, Ohio, August 6, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 ATRICURE, INC. |
|
| August 6, 2020 |
Offer Letter, dated August 6, 2020, by and between AtriCure, Inc. and Angela L. Wirick EX-10.1 2 d941955dex101.htm EX-10.1 Exhibit 10.1 7555 Innovation Way Mason, OH 45040 United States 513-755-4100 August 4, 2020 Angela Wirick Dear Angie, I am pleased to formally extend this offer to you for your promotion to the position of Chief Financial Officer. This letter will confirm the details of the offer. This formal offer will remain open until the close of business on August 6, 2020. P |
|
| July 30, 2020 |
S-8 1 d757929ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on July 30, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRICURE, INC. (Exact name of Registrant as Specified in its Charter) Delaware 34-1940305 (State Or Other Jurisdiction Of Incorporation Or Or |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| July 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2020 AtriCure, Inc. |
|
| July 28, 2020 |
AtriCure Reports Second Quarter 2020 Financial Results Exhibit 99.1 For immediate release July 28, 2020 AtriCure Reports Second Quarter 2020 Financial Results · Worldwide revenue of $40.8 million – a decrease of 30.7% year over year · U.S. revenue of $33.7 million – a decrease of 28.6% year over year · International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio, July 28, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading in |
|
| May 28, 2020 |
SD 1 atrc-20200528corresp.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 000-51470 (Commission File Number) 34-1940305 (IRS Employer Identification No.) 7555 Innovation Way Mason, OH (Address |
|
| May 28, 2020 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 This report for the year ended December 31, 2019 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict m |
|
| May 22, 2020 |
ATRICURE, INC. 2014 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 20, 2020) TABLE OF CONTENTS 1 Purpose 1 2 Definitions 1 3 Administration of the Plan 4 (a) Authority of Committee 4 (b) Binding Authority 5 (c) Delegation of Authority 5 4 Eligibility 6 5 Common Shares Subject to the Plan 6 (a) Authorized Number of Common Shares 6 (b) Share Counting 6 (c) Award Limitations. |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2020 ATRICURE, INC. |
|
| May 13, 2020 |
Title of Each Class of Securities to be Registered 424B5 1 d853725d424b5.htm 424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share $201,249,972 $26,122.25 (1) Assumes exercise in full of the underwriters’ option to purchase additional shares of common stock. (2) Calculated in accor |
|
| May 13, 2020 |
AtriCure Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 AtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio—(BUSINESS WIRE)—May 11, 2020— AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million |
|
| May 13, 2020 |
AtriCure Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 AtriCure Announces Pricing of Public Offering of Common Stock MASON, Ohio—(BUSINESS WIRE)—May 11, 2020 — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 pe |
|
| May 13, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2020 AtriCure, Inc. |
|
| May 13, 2020 |
EX-1.1 Exhibit 1.1 Execution Version ATRICURE, INC. 3,977,273 Shares of Common Stock Underwriting Agreement May 11, 2020 J.P. Morgan Securities LLC Piper Sandler & Co. as Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and |
|
| May 11, 2020 |
424B5 1 d853725d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-230001 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supp |
|
| May 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2020 AtriCure, Inc. |
|
| May 8, 2020 |
Exhibit 99.1 For immediate release May 8, 2020 AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; shows primary effectiveness superiority in favor of the hybrid Convergent procedure MASON, Ohio – (BUSINESS WIRE) – May 8, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| April 29, 2020 |
Exhibit 10.1 FOURTH AMENDMENT to Loan and security agreement This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 29th day of April, 2020, among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as Administrative Agent (“Agent”), (b) SVB, and each other lender and other financial institutions party to the Loan Agreement (as defin |
|
| April 29, 2020 |
Exhibit 99.2 AtriCure Investor Presentation Creating a World Class Afib Platform April 2020 1 © 2020 AtriCure, Inc. All rights reserved. AtriCure Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and act |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2020 AtriCure, Inc. |
|
| April 29, 2020 |
AtriCure Reports First Quarter 2020 Financial Results Exhibit 99.1 For immediate release April 29, 2020 AtriCure Reports First Quarter 2020 Financial Results · Worldwide revenue of $53.2 million – a decrease of 1.4% year over year · U.S. revenue of $43.5 million – an increase of 1.1% year over year · International revenue of $9.8 million – a decrease of 11.0% year over year MASON, Ohio, April 29, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading in |
|
| April 13, 2020 |
Exhibit 99.1 For immediate release April 13, 2020 AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting MASON, Ohio — April 13, 2020 — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from |
|
| April 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2020 AtriCure, Inc. |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2020 AtriCure, Inc. |
|
| April 9, 2020 |
Exhibit 99.1 For immediate release April 9, 2020 AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update MASON, Ohio — April 9, 2020 — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2 |
|
| April 8, 2020 |
ATRC / AtriCure, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 24, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi |
|
| February 24, 2020 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company Endoscopic Technologies, LLC, a Delaware limited liability company nContact Surgical LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, inc |
|
| February 24, 2020 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 24, 2020, AtriCure, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. General The following description of our common stock is a summary and does not pur |
|
| February 24, 2020 |
2020 (incorporated by reference to our Annual Report on Form 10-K filed on February 24, 2020). Exhibit 10.16 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN FORM OF PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agr |
|
| February 18, 2020 |
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results EX-99.1 2 atrc-20200218xex991.htm EX-99.1 Exhibit 99.1 For immediate release February 18, 2020 AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results · 2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year · 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year · 2019 International revenue of $45.0 million – an increase of 13.9% yea |
|
| February 18, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2020 AtriCure, Inc. |
|
| February 11, 2020 |
ATRC / AtriCure, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: AtriCure Inc Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1 |
|
| January 27, 2020 |
ATRC / AtriCure, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2020 ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 000-51470 (Commission File Number) 34-194030 |
|
| January 13, 2020 |
Exhibit 99.1 For immediate release January 13, 2020 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019 Provides Financial Outlook for 2020 MASON, Ohio, January 13, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarte |
|
| January 13, 2020 |
Exhibit 99.2 AtriCure Investor Presentation Creating a World Class Afib Platform January 2020 © 2020 AtriCure, Inc. All rights reserved. AtriCure 1 Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and a |
|
| December 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2019 AtriCure, Inc. |
|
| December 4, 2019 |
AtriCure Names Two Industry Veterans to Board of Directors Exhibit 99.1 For immediate release December 4, 2019 AtriCure Names Two Industry Veterans to Board of Directors MASON, Ohio-(BUSINESS WIRE) – December 4, 2019- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors |
|
| October 31, 2019 |
Exhibit 10.1 JOINDER AND THIRD AMENDMENT to Loan and security agreement This Joinder and Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 27th day of September, 2019, among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as Administrative Agent (“Agent”), (b) SVB, and each other lender and other financial institutions party to th |
|
| October 31, 2019 |
‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc. |
|
| October 30, 2019 |
AtriCure Reports Third Quarter 2019 Financial Results Exhibit 99.1 For immediate release October 30, 2019 AtriCure Reports Third Quarter 2019 Financial Results · Worldwide revenue of $56.6 million – an increase of 13.4% year over year · U.S. revenue of $46.1 million – an increase of 16.0% year over year · International revenue of $10.5 million – an increase of 3.1% year over year MASON, Ohio, October 30, 2019 – AtriCure, Inc. (Nasdaq: ATRC), a le |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2019 AtriCure, Inc. |
|
| October 25, 2019 |
EX-99.1 Exhibit 99.1 Independent Auditor’s Report To the Board of Directors and Stockholders SentreHEART, Inc. Report on the Financial Statements We have audited the accompanying consolidated financial statements of SentreHEART, Inc. (the Company) and its subsidiary, which comprise the consolidated balance sheets as of December 31, 2018 and 2017, the related consolidated statements of operations, |
|
| October 25, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. |
|
| October 25, 2019 |
EX-99.2 Exhibit 99.2 SentreHEART, Inc. Condensed Consolidated Balance Sheets June 30, 2019 and 2018 (unaudited) June 30, 2019 June 30, 2018 Assets Current assets: Cash and cash equivalents $ 2,611,513 $ 1,863,453 Accounts receivable 534,625 398,265 Inventory 651,703 749,097 Prepaid expenses and other current assets 51,289 87,913 Total current assets 3,849,130 3,098,728 Property and equipment, net |
|
| October 25, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2019 ATRICURE, INC. |
|
| October 25, 2019 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is presented to give effect to the acquisition of SentreHEART, Inc. (“SentreHEART”) by AtriCure, Inc. (“AtriCure” or the “Company”), or the Acquisition, as announced on August 11, 2019 and subsequently closed on August 13, 2019. The unaudited |
|
| October 25, 2019 |
424B7 Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-230001 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Amount to be Registered(2) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.001 per share 7,719,907 $26.26(3)(4) $202,724,758(4) $26,314(4) |
|
| August 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2019 ATRICURE, INC. |
|
| August 13, 2019 |
AtriCure Completes Acquisition of SentreHEART EX-99.1 2 d788489dex991.htm EX-99.1 Exhibit 99.1 For immediate release August 13, 2019 AtriCure Completes Acquisition of SentreHEART MASON, Ohio—(BUSINESS WIRE) –August 13, 2019— AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has completed its previously announced acquisition of Se |
|
| August 12, 2019 |
EX-10.1 Exhibit 10.1 CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Consent and Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 12th day of August, 2019, among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as Administrative Agent (“Agent”), (b) SVB, and each other lender and other financial institutions party to |
|
| August 12, 2019 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG SENTREHEART, INC., ATRICURE, INC., STETSON MERGER SUB, INC. SECOND STETSON MERGER SUB, LLC AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS SECURITYHOLDER REPRESENTATIVE Dated as of August 11, 2019 THIS DOCUMENT IS INTENDED SOLELY TO FACILITATE DISCUSSIONS AMONG THE PARTIES IDENTIFIED HEREIN. IT IS NOT INTENDED TO CREATE, AND WILL NOT BE |
|
| August 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2019 ATRICURE, INC. |
|
| August 12, 2019 |
EX-99.1 Exhibit 99.1 For immediate release August 11, 2019 AtriCure Enters into Definitive Agreement to Acquire SentreHEART Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio—(BUSINESS WIRE) –August 12, 2019— AtriCure, Inc. (Nasdaq: ATRC) |
|
| August 12, 2019 |
AtriCure – Transforming the AFib Market SentreHEART Transaction Overview and Strategic Rationale August 2019 © 2019 AtriCure, Inc. |
|
| July 31, 2019 |
ATRC / AtriCure, Inc. S-8 - - FORM S-8 S-8 1 d741323ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on July 31, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRICURE, INC. (Exact name of Registrant as Specified in its Charter) Delaware 34-1940305 (State Or Other Jurisdiction Of Incorporation Or Or |
|
| July 31, 2019 |
Exhibit 10.1 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN AMENDED AND RESTATED JULY 1, 2019 1.Purpose. The purposes of the Plan are as follows: (a)To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an “employee stock purchase plan” within the meaning |
